A case in which SGLT2 inhibitor is a contributing factor to takotsubo cardiomyopathy and heart failure

Haruyuki Kinoshita; Hiroshi Sugino; Toshiharu Oka; Orie Ichikawa; Takashi Shimonaga; Yoji Sumimoto; Ayano Kashiwabara; Takumi Sakai

doi:10.1016/j.jccase.2020.06.014

A case in which SGLT2 inhibitor is a contributing factor to takotsubo cardiomyopathy and heart failure

J Cardiol Cases. 2020 Jul 2;22(4):177-180. doi: 10.1016/j.jccase.2020.06.014. eCollection 2020 Oct.

Authors

Haruyuki Kinoshita¹, Hiroshi Sugino¹, Toshiharu Oka¹, Orie Ichikawa¹, Takashi Shimonaga¹, Yoji Sumimoto¹, Ayano Kashiwabara¹, Takumi Sakai¹

Affiliation

¹ Division of Cardiology National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.

Abstract

SGLT2 inhibitors are reported to have advantages in protecting against heart failure events. However, there are also reports of concerns when given to older persons or persons with geriatric syndrome. Our case is an example of a patient with a history of chronic thyroiditis where the SGLT2 inhibitor triggered a thyroid crisis, and blood catecholamine overload caused takotsubo cardiomyopathy and heart failure. <Learning objective: SGLT2 inhibitor is a type of medicine for diabetes that has been used frequently. But if we are not careful about underlying disease and clinical course, it might lead to exacerbation of heart failure.>.

Keywords: Heart failure; SGLT2 inhibitor; Takotsubo cardiomyopathy; Thyroid crisis.